British drugs firm GSK settles US drug disputes for $3.0 bln
November 3, 2011 in MedicationsGlaxoSmithKline said on Thursday it had agreed to pay $3.0 billion (2.2 billion euros) to settle long-running disputes with the US government over how the British pharmaceuticals group marketed and developed drugs.
GlaxoSmithKline said in a statement that it had "reached an agreement in principle with the US government to conclude the company's most significant ongoing Federal government investigations."
The investigations included the probing of GSK's sales and marketing practices, begun by the US Attorney's office of Colorado in 2004 and later taken over by the US Attorney's Office of Massachusetts.
And they also referred to the Department of Justice's probe into the development and marketing of its former blockbuster diabetes drug Avandia.
GSK said that it had already set aside sufficient cash funds to pay the legal costs, although some terms still needed to be agreed.
GSK chief executive Andrew Witty said the $3.0 billion deal was "a significant step toward resolving difficult, long-standing matters which do not reflect the company that we are today."
He added in a statement: "In recent years, we have fundamentally changed our procedures for compliance, marketing and selling in the US to ensure that we operate with high standards of integrity and that we conduct our business openly and transparently."
(c) 2011 AFP
-
GlaxoSmithKline reports return to profit in second quarter
Jul 26, 2011 |
not rated yet |
0
-
Drugs firm GSK eyes India acquisitions: chief executive
Oct 03, 2011 |
not rated yet |
0
-
GSK to take $3.4 bln Avandia legal charge
Jan 17, 2011 |
not rated yet |
0
-
GlaxoSmithKline posts rising Q3 profits
Oct 26, 2011 |
not rated yet |
0
-
Glaxo pays 41 million to settle US drug quality matter
Jun 23, 2011 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
May 25, 2012 |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (4) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Potential Breakthrough in Seizure Control
9 hours ago
-
Popping/Cracked sternum.
14 hours ago
-
Which Mental Illness Encompasses This Problem?
14 hours ago
-
A question about drug tolerance
May 23, 2012
-
Poor nutrition leading to overeating?
May 23, 2012
-
Math and dyslexia?
May 21, 2012
- More from Physics Forums - Medical Sciences
More news stories
Missouri opts for untested drug for executions
(AP) -- The same anesthetic that caused the overdose death of pop star Michael Jackson is now the drug of choice for executions in Missouri, causing a stir among critics who question how the state can guarantee ...
Medications
May 24, 2012 |
not rated yet |
4
Aspirin may prevent recurrence of deep vein blood clots
(HealthDay) -- After suffering a type of blood clot called a venous thromboembolism, patients usually take a blood-thinner such as warfarin (Coumadin). But aspirin may do just as well after a period of time, ...
Medications
May 23, 2012 |
not rated yet |
2
|
Patients may receive too much acetaminophen in hospital
(HealthDay) -- Roughly 2.5 percent of admitted hospital patients may receive more than the safe daily cumulative dose of the pain-reliever acetaminophen, best known as Tylenol, on at least one day, according ...
Medications
May 23, 2012 |
1 / 5 (1) |
0
New quality standards limiting elemental impurities in medicines announced
As part of its ongoing efforts to help ensure the quality of medicines, the U.S. Pharmacopeial Convention (USP) has announced two new standards related to elemental impurities: General Chapters Elemental Impurities—Limits and ...
Medications
May 23, 2012 |
not rated yet |
0
Quality standards for heparin further strengthened
To help further secure a safe supply of the widely–used blood thinner heparin, a third round of revisions to quality standards for the drug has been advanced by the U.S. Pharmacopeial Convention (USP). USP's Expert Panel ...
Medications
May 23, 2012 |
not rated yet |
0
Travel to high altitudes tied to Crohn's, colitis flare-ups
(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...
Family history of Alzheimer's affects functional connectivity
(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...
Transvaginal mesh op restores pelvic organ prolapse at price
(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...
Tongue analysis software uses ancient Chinese medicine to warn of disease
For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...
Skp2 activates cancer-promoting, glucose-processing Akt
HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.
Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare
A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...
